CAL
NVCR icon

Capital Advisors Ltd’s NovoCure NVCR Stock Holding History

Capital Advisors Ltd’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21
Closed – – 1501
2025
Q2 		$0 Hold
21
– – ﹤0.01% 1548
2025
Q1 		$0 Hold
21
– – ﹤0.01% 1514
2024
Q4 		$1K Hold
21
– – ﹤0.01% 1261
2024
Q3 		$0 Hold
21
– – ﹤0.01% 1542
2024
Q2 		$0 Sell
21
-367
-95% -$6.45K ﹤0.01% 1569
2024
Q1 		$6K Buy
388
+368
+1,840% +$5.41K ﹤0.01% 846
2023
Q4 		$0 Buy
20
+10
+100% +$134 ﹤0.01% 1426
2023
Q3 		$0 Buy
+10
New +$288 ﹤0.01% 1414
2023
Q1 		– Sell
-2
Closed – – 1444
2022
Q4 		$0 Sell
2
-20
-91% -$1.5K ﹤0.01% 1506
2022
Q3 		$2K Buy
22
+12
+120% +$936 ﹤0.01% 880
2022
Q2 		$1K Buy
10
+4
+67% +$301 ﹤0.01% 843
2022
Q1 		$0 Buy
+6
New +$442 ﹤0.01% 1119

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Advisors Ltd's NVCR Position: Q3 2025 in Review

Capital Advisors Ltd sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 21 shares.

Capital Advisors Ltd first reported a position in NVCR in Q1 2022 and held it in 12 quarters. The position peaked at $6K in Q1 2024. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Capital Advisors Ltd reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Capital Advisors Ltd sold 21 NovoCure shares in Q3 2025.
  • Capital Advisors Ltd first reported a position in NovoCure in Q1 2022 and held it in 12 quarters.
  • Capital Advisors Ltd's NovoCure position peaked at $6K in Q1 2024.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Capital Advisors Ltd's 13F filing for Q3 2025, filed 16 Oct 2025.